April 23, 2021
April 23, 2021 – The U.S. FDA has approved ZynlontaTM (loncastuximab tesirine-lpyl), manufactured by ADC
Therapeutics, to treat adults who have relapsed or refractory large B-cell lymphoma
- Have any questions?
- +1-888-INTL-SOS
- support@globalreachhealth.com
GlobalReach Health
April 22, 2021
April 22, 2021 – The U.S. FDA has granted accelerated approval to Jemperli® (dostarlimab-gxly),
manufactured by GlaxoSmithKline, to treat mismatch repair deficient (dMMR)
April 21, 2021
April 21, 2021 – The U.S. FDA has approved an expanded indication for Evekeo® ODT (amphetamine
sulfate) orally disintegrating tablets, manufactured by Arbor Pharmaceuticals.
April 21, 2021
April 21, 2021 – The U.S. FDA has approved an expanded indication for Diovan® (valsartan) oral tablets,
manufactured by Novartis, to treat hypertension in patients who are at least one year of age
April 19, 2021
April 19, 2021 – The U.S. FDA has approved an expanded indication for Ragwitek® (short ragweed pollen allergen extract) sublingual tablets to treat short ragweed pollen-induced allergic
April 16, 2021
April 16, 2021 – The U.S. FDA has approved Nextstellis® (3mg drospirenone/14.2mg estetrol
tablets), manufactured by Mayne Pharma, for use by females of reproductive potential
April 16, 2021
April 16, 2021 – The U.S. FDA has revoked emergency use authorization (EUA) for bamlanivimab, an investigational drug manufactured by Eli Lilly
April 16, 2021
April 16, 2021 – The U.S. FDA has approved a new indication for Opdivo® (nivolumab), manufactured by Bristol Myers Squibb. The drug is now indicated for use in combination with fluoropyrimidine